Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diab...

Related Keywords

Delaware ,United States ,California ,Emeryville ,Adam Mendelsohn ,Bydureon Bcise ,Development Expense ,Nasdaq ,Exchange Commission The ,Biopharm Division ,Exchange Commission ,Vivani Neuromodulation Division ,Company Biopharm Division ,Commission On ,Cortigent Inc ,Vivani Medical Inc ,Drug Administration ,Neuromodulation Division ,Vivani Medical ,Chief Executive Officer ,Nano Precision Medical ,Second Sight Medical Products ,Investigational New Drug ,Second Sight ,Registration Statement ,Administrative Expense ,Securities Litigation Reform Act ,Annual Report ,Ended December ,